IL-28A/IFN-λ2 Recombinant Rabbit mAb (SDT-1616-14)
IL-28A/IFN-λ2 Recombinant Rabbit mAb (SDT-1616-14)
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | IL-28A |
| Synonyms | IL-28A/IFN-λ2 |
| Immunogen | Recombinant Protein |
| Accession | Q8IZI9、Q8IZJ0 |
| Clone Number | SDT-1616-14 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | Sandwich ELISA |
| Reactivity | Hu |
| Cross Reactivity | No cross-reactivity against human IL-29 and IL-28B, only recognize IL-28A. |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Purity | >95% by HPLC |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, 0.03% Proclin 300 |
| Stability & Storage | 12 months from date of receipt, 2 to 8 °C as supplied |
Background
Interleukin-28A (IL-28A), also known as interferon lambda-2 (IFN-λ2), is a member of the type III interferon family. It is produced in response to viral infections and plays a critical role in the innate immune response. IL-28A exhibits antiviral activity by inducing the expression of interferon-stimulated genes (ISGs) and activating immune cells to inhibit viral replication and spread. IL-28A is primarily expressed by immune cells, such as dendritic cells and macrophages, and acts through the IFN-λ receptor complex to exert its antiviral effects. Due to its role in antiviral defense and immune regulation, IL-28A has garnered significant interest as a potential therapeutic target for viral infections, including hepatitis C and respiratory viruses.
Picture
Picture
Paired Recommendations
